NextCure, Inc.(NXTC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 30 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NXTC Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for NextCure, Inc. (NXTC), a Healthcare sector company. NXTC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 30 institutional filers currently hold this stock. Top institutional holders of NXTC by reported 13-F value include Ikarian Capital, ADAGE CAPITAL PARTNERS GP, L.L.C., Sofinnova Ventures, based on the most recent SEC filings. NXTC trades on the Nasdaq exchange and files with the SEC under CIK 1661059. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NXTC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NextCure, Inc. directly from SEC EDGAR. NextCure, Inc.'s 13F Pro composite quality score has ranged between 7 and 38 since 2021, currently 9.2 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.
Net Income
Q2 2026
$-14.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-0.3% YoYOperating Income
+3.6% YoYEPS (Diluted)
+17.7% YoYTotal Assets
-37.9% YoYTotal Debt
Op. Cash Flow
-21.6% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $22.4M |
| Net Income | $-55.8M -0.3% | $-55.7M +11.3% | $-62.7M +16.1% | $-74.7M -7.7% | $-69.4M -89.6% | $-36.6M |
| Operating Income | $-57.6M +3.6% | $-59.7M +11.7% | $-67.6M +10.9% | $-75.9M -7.3% | $-70.8M -71.7% | $-41.2M |
| EPS (Diluted) | $-19.65 +17.7% | $-23.88 -961.3% | $-2.25 +16.4% | $-2.69 -7.2% | $-2.51 -88.7% | $-1.33 |
| Total Assets | $50.2M -37.9% | $80.9M -36.8% | $128.0M -30.5% | $184.2M -24.0% | $242.4M -21.0% | $306.6M |
| Total Debt | — | — | — | $0.00 | $0.00 -100.0% | $5.1M |
| Operating Cash Flow | $-49.6M -21.6% | $-40.8M +23.0% | $-53.0M +1.7% | $-53.9M +5.9% | $-57.3M -27.4% | $-45.0M |
| Free Cash Flow | — | $-41.3M +23.3% | $-53.8M +3.9% | $-56.0M +6.1% | $-59.6M -14.5% | $-52.1M |
Get alerted when NXTC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for NextCure, Inc. including:
Top Institutional Holders of NXTC
Ikarian Capital, LLC
$461.3K288,303 shADAGE CAPITAL PARTNERS GP, L.L.C.
$443.5K277,202 shSofinnova Ventures Inc
$356.2K222,654 shRENAISSANCE TECHNOLOGIES LLC
$273.9K171,202 shVANGUARD CAPITAL MANAGEMENT LLC
$250.9K156,842 shMILLENNIUM MANAGEMENT LLC
$141.0K88,112 shBOOTHBAY FUND MANAGEMENT, LLC
$135.5K84,687 shSquadron Capital Management LLC
$103.1K64,464 shVerdad Advisers, LP
$96.7K60,451 shPFIZER INC
$73.0K44,347 sh
| Fund | Value | Shares |
|---|---|---|
| Ikarian Capital, LLC | $461.3K | 288,303 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $443.5K | 277,202 |
| Sofinnova Ventures Inc | $356.2K | 222,654 |
| RENAISSANCE TECHNOLOGIES LLC | $273.9K | 171,202 |
| VANGUARD CAPITAL MANAGEMENT LLC | $250.9K | 156,842 |
| MILLENNIUM MANAGEMENT LLC | $141.0K | 88,112 |
| BOOTHBAY FUND MANAGEMENT, LLC | $135.5K | 84,687 |
| Squadron Capital Management LLC | $103.1K | 64,464 |
| Verdad Advisers, LP | $96.7K | 60,451 |
| PFIZER INC | $73.0K | 44,347 |
More Healthcare Companies
View all Healthcare →Put NXTC on your watchlist
Track score changes the day NextCure, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NXTC a good stock to buy?
13F Pro's AI-powered analysis of NextCure, Inc. (NXTC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NXTC are available on the NXTC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NXTC is classified as a small company.
Which hedge funds own NXTC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NXTC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NextCure, Inc.'s investment landscape.